Dr. Jason William Denbo, MD

Dr. Denbo practices at H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida.

Dr. Denbo's NPI, 1346432572, was assigned on August 12, 2007. Dr. Denbo graduated from Indiana University School Of Medicine in 2007. Dr. Denbo's Minnesota license number on file is 62506.

Dr. Denbo's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD, at 10901 McKinley Dr, Tampa, FL 33612.

Dr. Denbo's primary practice is H Lee Moffitt Cancer Center & Research Institute I - HOPD in Tampa, Florida. Dr. Denbo is also affiliated with Moffitt Cancer Hospital. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Denbo to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Denbo practices, 3 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Denbo's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Denbo is board certified in complex general surgical oncology by the American Board of Surgery. Dmand AI has Dr. Denbo's licenses on file in 3 states: Minnesota, Florida and Texas.

Dmand AI lists acute gallbladder or bile duct inflammation, colon removal and gallbladder removal among the conditions Dr. Denbo treats.

CMS data shows 71 Medicare services from Dr. Denbo across 5 procedure codes in 2024, for 79 Medicare patients. Medicare paid $42,785 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 79 Medicare patients who saw Dr. Denbo in 2024. The largest group is 65 to 74, with 48 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Denbo's median patient age at 68, with 48% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Denbo for performance year 2024, reported as part of a group. Dr. Denbo accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Denbo as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 66 papers to Dr. Denbo, published from 2012 to 2025. 2022 was the busiest year, with 10. The most frequent topics are Pancreatic Neoplasms, Adenocarcinoma and Carcinoma, Pancreatic Ductal. Dr. Denbo has published most often in Ann Surg Oncol. Dr. Denbo's most frequent co-authors are Jason Bates Fleming, MD, Daniel A. Anaya, MD and Jason B. Fleming, MD.

CMS Open Payments shows 81 general payments to Dr. Denbo from 15 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 56% of the total. Medtronic, Inc. paid the most, $16,068.

Dmand AI lists 1 award for Dr. Denbo.

Dr. Denbo graduated from Indiana University School Of Medicine in 2007. Dr. Denbo is a member of ACS.

Dr. Denbo is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.